You limited your search to:

 Country: United States
 Decade: 2000-2009
 Collection: Congressional Research Service Reports
Federal R&D, Drug Discovery, and Pricing: Insights from the NIH-University-Industry Relationship

Federal R&D, Drug Discovery, and Pricing: Insights from the NIH-University-Industry Relationship

Date: June 19, 2000
Creator: Schacht, Wendy H
Description: Interest in methods to provide drugs at lower cost, particularly for the elderly, has rekindled discussion over the role the federal government plays in facilitating the creation of new pharmaceuticals for the marketplace. This report explores the issue of whether or not the substantial federal investment in health-related research and development (R&D) entitles the public to commensurate consideration in prices charged for any resulting drugs. It is intended to provide the reader with an understanding of the rationale for government support of R&D and subsequent efforts to facilitate private sector commercialization of new technologies generated from such work. Concerns surrounding innovation in pharmaceuticals and biotechnology are discussed within the broader context of the federal role in facilitating technological progress.
Contributing Partner: UNT Libraries Government Documents Department
Medical Records Privacy: Questions and Answers on the HIPAA Final Rule

Medical Records Privacy: Questions and Answers on the HIPAA Final Rule

Date: September 10, 2001
Creator: Redhead, C. Stephen
Description: This report discusses the issue facing Congress on whether to continue to support the executive branch’s prosecution of medical marijuana patients and their providers, in accordance with marijuana’s status as a Schedule I drug under the Controlled Substances Act, or whether to relax federal marijuana prohibition enough to permit the medical use of botanical cannabis products by seriously ill persons, especially in states that have created medical marijuana programs under state law.
Contributing Partner: UNT Libraries Government Documents Department
Medical Records Privacy: Questions and Answers on the HIPAA Final Rule

Medical Records Privacy: Questions and Answers on the HIPAA Final Rule

Date: October 3, 2002
Creator: Redhead, C. Stephen
Description: This report discusses the issue facing Congress on whether to continue to support the executive branch’s prosecution of medical marijuana patients and their providers, in accordance with marijuana’s status as a Schedule I drug under the Controlled Substances Act, or whether to relax federal marijuana prohibition enough to permit the medical use of botanical cannabis products by seriously ill persons, especially in states that have created medical marijuana programs under state law.
Contributing Partner: UNT Libraries Government Documents Department
Medical Records Privacy: Questions and Answers on the HIPAA Final Rule

Medical Records Privacy: Questions and Answers on the HIPAA Final Rule

Date: January 3, 2003
Creator: Redhead, C. Stephen
Description: This report discusses the issue facing Congress on whether to continue to support the executive branch’s prosecution of medical marijuana patients and their providers, in accordance with marijuana’s status as a Schedule I drug under the Controlled Substances Act, or whether to relax federal marijuana prohibition enough to permit the medical use of botanical cannabis products by seriously ill persons, especially in states that have created medical marijuana programs under state law.
Contributing Partner: UNT Libraries Government Documents Department
Medical Records Privacy: Questions and Answers on the HIPAA Final Rule

Medical Records Privacy: Questions and Answers on the HIPAA Final Rule

Date: June 11, 2003
Creator: Redhead, C. Stephen
Description: This report discusses the issue facing Congress on whether to continue to support the executive branch’s prosecution of medical marijuana patients and their providers, in accordance with marijuana’s status as a Schedule I drug under the Controlled Substances Act, or whether to relax federal marijuana prohibition enough to permit the medical use of botanical cannabis products by seriously ill persons, especially in states that have created medical marijuana programs under state law.
Contributing Partner: UNT Libraries Government Documents Department
Medical Records Privacy: Questions and Answers on the HIPAA Final Rule

Medical Records Privacy: Questions and Answers on the HIPAA Final Rule

Date: March 10, 2004
Creator: Redhead, C. Stephen
Description: This report discusses the issue facing Congress on whether to continue to support the executive branch’s prosecution of medical marijuana patients and their providers, in accordance with marijuana’s status as a Schedule I drug under the Controlled Substances Act, or whether to relax federal marijuana prohibition enough to permit the medical use of botanical cannabis products by seriously ill persons, especially in states that have created medical marijuana programs under state law.
Contributing Partner: UNT Libraries Government Documents Department
The Global Fund and PEPFAR in U.S. International AIDS Policy

The Global Fund and PEPFAR in U.S. International AIDS Policy

Date: November 3, 2005
Creator: Copson, Raymond W.
Description: The international HIV/AIDS pandemic continues to deepen. According to UNAIDS, the Joint United Nations Program on HIV/AIDS, an estimated 39.4 million people were living with HIV in 2004, including 4.9 million who were newly infected during the year. This report discusses the President’s Emergency Plan for AIDS Relief (PEPFAR), which includes bilateral programs and contributions to the multilateral Global Fund for AIDS, Tuberculosis, and Malaria.
Contributing Partner: UNT Libraries Government Documents Department
Influenza Antiviral Drugs and Patent Law Issues

Influenza Antiviral Drugs and Patent Law Issues

Date: November 18, 2005
Creator: Yeh, Brian T.
Description: This report identifies and analyzes the patent law aspects of the current avian influenza drug situation. First, the report explains the role that patent rights have played in affecting the availability of Tamiflu. Second, the report examines options for increasing the drug’s production, including the possibility of governments abrogating Roche’s patent rights by issuing compulsory licenses to other drug companies to manufacture generic versions of Tamiflu without Roche’s consent.
Contributing Partner: UNT Libraries Government Documents Department
HIV/AIDS International Programs: Appropriations, FY2003-FY2006

HIV/AIDS International Programs: Appropriations, FY2003-FY2006

Date: January 3, 2006
Creator: Salaam-Blyther, Tiaji
Description: This report briefly discusses appropriations for international HIV/AIDS programs. FY2006 Appropriations for Foreign Operations (P.L. 109-102), Labor/HHS/Education (H.Rept. 109-300), Defense, and Agriculture (P.L. 109-97) provide more than $3.4 billion for international HIV/AIDS, tuberculosis (TB), and malaria initiatives. The largest portion of the funds is provided through P.L. 109-102, which directs more than $2.8 billion to fighting the three diseases.
Contributing Partner: UNT Libraries Government Documents Department
FDA Regulation of Tobacco Products: A Policy and Legal Analysis

FDA Regulation of Tobacco Products: A Policy and Legal Analysis

Date: December 3, 2004
Creator: Redhead, C. Stephen & Feder, Jody
Description: This report examines the legislative debate over giving FDA the authority to regulate tobacco products and provides some analysis of S. 2461/H.R. 4433. It begins with an overview of the FDA’s 1996 tobacco rule that includes a summary of the agency’s arguments for asserting jurisdiction over tobacco products. That is followed by an analysis of the U.S. Supreme Court decision in FDA v. Brown & Williamson, which overturned the FDA tobacco rule. The report then reviews the 1997 proposed national tobacco settlement, which would have codified the FDA rule and given the agency explicit authority to regulate tobacco products as medical devices. It includes a discussion of the FDA provisions in the McCain tobacco bill, which was introduced and debated in the 105th Congress in an attempt to implement the proposed settlement. The final section of the report summarizes the provisions in S. 2461/H.R. 4433 and discusses some of the key issues, including preemption and the regulation of reduced-risk products.
Contributing Partner: UNT Libraries Government Documents Department
FIRST PREV 1 2 3 4 5 NEXT LAST